NCT05659251 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
Clinical Trials
15 trialsNCT06576973 2025-12-02
Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Recruiting
NCT07244978 2025-12-02
Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Not yet recruiting
NCT04666090 2025-05-15
Carrelizumab, Chemotherapy and Apatinib in the Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT00318903 2023-05-25
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT02965976 2023-02-16
Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT05596890 2022-11-28
PICCRT
Guangdong Provincial People's Hospital
Phase 2 Unknown
NCT05245760 2022-11-08
CRATER
University of Kentucky
Phase 2 Withdrawn
NCT03529266 2021-08-24
PLACE020
Sun Yat-sen University
Phase 2 Completed
NCT04006041 2019-12-26
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Sun Yat-sen University
Phase 2 Unknown
NCT02858206 2019-07-26
Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
ChineseAMS
Phase 2 Unknown
NCT01372202 2019-01-25
J10130
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT03223662 2018-10-30
Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00137852 2017-09-20
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01349517 2011-11-11
Health-related Quality of Life of Patients With Esophageal Cancer After Surgery
Fudan University
Phase 2 Unknown